Loading...
Carmell Therapeutics Corporation
CTCXW•NASDAQ
HealthcareBiotechnology
$0.03
$-0.02(-45.40%)
Carmell Therapeutics Corporation (CTCXW) Stock Overview
Explore Carmell Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for CTCXWStats details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for CTCXWAnalyst Recommendations details for CTCXW are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Company Profile
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.
CEO
Mr. Rajiv Sarman Shukla
Employees
9
Headquarters
2403 Sidney Street, Pittsburgh, PA
Founded
1970